Immuno-Oncology

Blogs

Multiplex Tissue Analysis + Digital Pathology in Clinical Research – A Summary of ASCO 2021 Findings

Background The range of technologies that enable multiplex tissue analysis (MTA) and digital pathology (DigPath) are rapidly growing and entering the clinical research space, providing new means of characterizing the

Navigating Companion Diagnostics (CDx) – Multiple Stakeholders, Many Goals

Background Companion diagnostic (CDx) tests are a foundational tool in precision medicine, helping ensure only the right patients receive the right therapies. The past several years have seen an explosion

Combination Therapies With OVs and ICIs May Increase the Success of Both Therapies

  Introduction Many strategies are being implemented to develop companion diagnostic tests in addition to adjuvant / combination therapies in order to bolster responses to immunotherapies.  In 2018, only an

DeciBio’s Spatial Omics Q&A with Ben Hindson, CSO for 10x Genomics

  On February 24th, 10x Genomics hosted their first Xperience event, which showcased the next wave of innovations for their three product verticals: Chromium, Visium, and the upcoming in situ

Spatial Omics Year in Review (2020): Transcriptomics Takes Center Stage

  While most industries slowed down in response to the global pandemic in 2020, the field of spatial omics certainly did not. Established companies and startups continued to announce products,

Update on the Adoption And Utilization of Emerging Precision Medicine Biomarkers and Technologies in Routine Clinical Care

At DeciBio Consulting, our mission is to provide market intelligence and insights to advance precision medicine.  To this end, we track this space closely, especially the field of precision oncology,

Cancer Immunotherapy Biomarker Spotlight: Immune Function Markers / Analyses

We’ve been tracking the cancer immunotherapy biomarker space closely via our Immuno-Oncology BioMAP for years and have witnessed the rapid growth and evolution of immuno-oncology first hand.  The amount of

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light

Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.